The NAMS 2022 Hormone Therapy Position Statement confirms that FDA-approved preparations are the preferred first-line option for menopausal symptom management
Key limitations include a small number of studies, variation in design, and a lack of focus on post-treatment outcomes in some trials
Such an environment encompasses the interrelated issues of exposure to high-density, highly caloric foods, the relatively low cost of these foods, and physical environments that limit the scope of physical activity [13]
Telehealth access expanding: Platforms like Klarity offer same-day access to 2,000+ licensed providers
But because there arent published human clinical trials on KPV, we simply dont yet know how this translates to humans, what dosing ranges are best, or whether it's safe over the long term
Well keep you updated on the progress of your order throughout production